Feed IPA
IP

ImmunoPrecise Antibodies Ltd.

IPA · NASDAQ

$1.62 +2.53% (+$0.04)
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Valuation
-
N/A
P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A
ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A
Debt/Assets N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
73 /100
Stable
Beta 0.49x
Profitable years N/A
Rev. volatility N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o IPA
Online

O podjetju

ImmunoPrecise Antibodies Ltd. (IPA) is a biotechnology company specializing in the development and production of monoclonal antibodies for research, diagnostics, and therapeutic purposes. Headquartered in Canada, the company operates globally, offering services related to antibody generation and characterization, including the development of anti-cancer and immunotherapeutic antibodies. ImmunoPrecise Antibodies focuses on providing high-quality and specialized products for various industries and research institutions. Shares of ImmunoPrecise Antibodies Ltd. (IPA) are listed on the Canadian stock exchange and can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jennifer Lynne Bath

Employees

72

Headquarters

Austin

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.